Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | HTR2C | P28335 | 5/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113388 | 0.76 | CYP11B1 (0.44) | PDE10A | |
| SCHEMBL25819925 | 0.75 | KDM4E (0.38) | HTR2AHTR2C | |
| SCHEMBL25819938 | 0.73 | HTR2A (0.38) | HTR2AHTR2C | |
| SCHEMBL25820060 | 0.70 | GAA (0.45) | HTR2AHTR2C | |
| SCHEMBL21503461 | 0.70 | GABRA1 (0.50) | HTR2AHTR2C | |
| SCHEMBL27317358 | 0.69 | CYP11B1 (0.37) | HTR2AHTR2CCTDSP1TDP1ACHE | |
| SCHEMBL21845759 | 0.69 | PDE10A (0.38) | PDE10AACHE | |
| SCHEMBL17981146 | 0.68 | TDP1 (0.37) | CYP19A1CTDSP1TDP1ACHE | |
| SCHEMBL30188824 | 0.68 | TDP1 (0.37) | CYP19A1CTDSP1TDP1ACHE | |
| SCHEMBL30702097 | 0.68 | BACE1 (0.41) | CTDSP1TDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PDE10A 529/4885HTR2A 2819/4885HTR2C 2539/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | PDE10A 611/4885HTR2A 2539/4885HTR2C 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.